RCMI Coordinating Center (RCMI CC) Header Logo

Jorge Duconge

TitlePhD
Faculty RankProfessor
InstitutionUniversity of Puerto Rico
DepartmentSchool of Pharmacy
AddressUPR-Medical Sciences Campus, School of Pharmacy
San Juan PR 936
Phone7877582525 ext. 5312
Fax7877672796
vCardDownload vCard
    Other Positions
    TitleInvestigator (WOC)
    InstitutionVA Caribbean Healthcare System
    DepartmentPharmacy

    TitleCollaborator
    InstitutionHartford Hospital


    Collapse Biography 
    Collapse awards and honors
    1995Summa Cum Laude, University of Havana, Cuba
    1999Best PhD Thesis in Pharmaceutical Sciences, National Council of Scientific Degrees, Cuba
    2002Annual National Prize of Health Sciences, Cuban Public Health Services
    2006 - 2009Teacher of the Year, School of Pharmacy, UPR-MSC
    2007Grant#5P20RR01112, Clinical Research Center infrastructure initiative Pilot Projects Award (RCRII), NIH
    2008Grant#5G11HDO46326, EARDA Program, NICHD, NIH
    2008 - 2011RCMI Mentorship Award, UPR-MSC RCMI Program; NCRR, NIH
    2011 - 2014Grant#HL110393, PGt of Warfarin in Puerto Rican Patients using a Physiogenomics Approach (SC2), NHLBI, NIH
    20132013 ASHP Foundation Literature Award , American Society of Health-System Pharmacists (ASHP)
    2014 - 2018Grant#HL123911, Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics (SC1), NHLBI, NIH
    2017 - 2022Grant#U54MD007600/5318, Adopting a Precision Medicine Paradigm in Puerto Ricans on Clopidogrel, RCMI, NIMHD, NIH
    2021Recognition for outstanding scientific productivity, Hispanic Alliance for Clinical and Translational Research
    2020Annual Cuban Academy of Sciences Award, Cuban Academy of Sciences

    Collapse Overview 
    Collapse overview
    Dr. Jorge Duconge is a Professor of Pharmacokinetics and Pharmacogenomics in the Department of Pharmaceutical Sciences at the School of Pharmacy, University of Puerto Rico Medical Sciences Campus.
    Dr. Duconge obtained a Baccalaureate in Pharmacy, BSc Pharm (1995, Gold Medal Honors List); Master’s degree in Experimental Pharmacology (1997); and a PhD degree (1999) from the School of Pharmacy, University of Havana. He also completed an advanced Residential Program in pharmacokinetics at Cambridge University, UK in 1998; population pharmacokinetics at State University of New York at Buffalo in 2006, and pharmacometrics (University of Auckland in New Zealand, 2003). He has also spent a mini-sabbatical at Hartford Hospital and the Genomas Laboratory of Personalized Health, CT in 2007, receiving hands-on training on DNA-typing. In addition, he completed the Genetic Analysis for Admixture and Epidemiology Studies in Latin American Populations (University of California at San Francisco (UCSF), USA) in 2010 and a hands-on workshop in next generation sequencing at the University of Pittsburgh/ Pittsburgh Supercomputing Center in 2013.
    His research areas include pharmacogenomics, pharmacokinetics, pharmacometrics and kinetics of drug action. From 1999 to 2004, Dr. Duconge headed the Pharmacokinetic Lab, Center for Biological Evaluation and Research in Havana, performing over 34 research projects and receiving 4 research grants. Since 2005 to date, he has completed various pharmacogenetic studies to determine prevalence of multiple pharmacogenes in the Puerto Rican population and their clinical association to medical outcomes. He also developed a novel PGt-guided algorithm to predict optimal warfarin doses in Puerto Ricans and measures of admixture pattern in this minority population. Moreover, a pharmacokinetic study of intermittent intravenous vitamin C infusions at high doses in prostate cancer patients was conducted. Currently, he is working on the physiogenomic analysis of the Caribbean Hispanics in order to infer their population structure and admixture pattern by using physiogenomic and ancestry markers, and also conducting pharmacogenetic association studies and implementing a DNA-guided algorithm for optimal warfarin management and dosing in Caribbean Hispanics. He is the author of more than 50 scientific publications including reviews, book chapters and research articles in peer-reviewed journals.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Morales P, Santiago L, Rosario J, Garcia-Fragoso L, Duconge J, Perez N, Santiago D. Neonatal Abstinence Syndrome and Corresponding Pharmacotherapy Approaches from 2 University-affiliated Neonatal Intensive Care Units in Puerto Rico (2018-2020). P R Health Sci J. 2024 Mar; 43(1):25-31. PMID: 38512758.
      Citations:    Fields:    Translation:Humans
    2. Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977. PMID: 38056237.
      Citations:    Fields:    Translation:Humans
    3. Nu?ez-Medina H, Monero M, Torres LM, Leal E, Gonz?lez-Sep?lveda L, Mayor ?M, Renta JY, Gonz?lez-Garc?a ER, Gonz?lez A, Melin K, Scott SA, Rua?o G, Hernandez-Suarez DF, Duconge J. Implementing a Pharmacogenomic-driven Algorithm to Guide Antiplatelet Therapy among Caribbean Hispanics: A non-randomized prospective cohort study. medRxiv. 2023 Dec 06. PMID: 38106133.
      Citations:    
    4. Yang G, Gonz?lez P, Moner? M, Carrasquillo K, Renta JY, Hernandez-Suarez DF, Botton MR, Melin K, Scott SA, Rua?o G, Roche-Lima A, Alarcon C, Ritchie MD, Perera MA, Duconge J. Discovery of Ancestry-specific Variants Associated with Clopidogrel Response among Caribbean Hispanics. medRxiv. 2023 Oct 02. PMID: 37873439.
      Citations:    
    5. Monero-Paredes M, Feliu-Maldonado R, Carrasquillo-Carrion K, Gonzalez P, Rogozin IB, Roche-Lima A, Duconge J. Non-Random Enrichment of Single-Nucleotide Polymorphisms Associated with Clopidogrel Resistance within Risk Loci Linked to the Severity of Underlying Cardiovascular Diseases: The Role of Admixture. Genes (Basel). 2023 09 17; 14(9). PMID: 37761953.
      Citations:    Fields:    Translation:Humans
    6. Hernandez-Martinez V, Duconge J, Rua?o G. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance? J Appl Lab Med. 2023 07 05; 8(4):826-830. PMID: 37228092.
      Citations: 1     Fields:    Translation:Humans
    7. Steiner HE, Carrion KC, Giles JB, Lima AR, Yee K, Sun X, Cavallari LH, Perera MA, Duconge J, Karnes JH. Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. Clin Pharmacol Ther. 2023 03; 113(3):680-691. PMID: 36321873.
      Citations:    Fields:    Translation:Humans
    8. Botton MR, Duconge J, Rodrigues-Soares F. Editorial: Pharmacogenomics in neglected populations. Front Pharmacol. 2022; 13:1081117. PMID: 36438814.
      Citations:    
    9. Morales-Borges RH, Gonzalez MJ, Duconge J, Minich DM. N-Acetyl Cysteine and Glutathione in Health and Cancer-Pharmacogenomics, Research, and Clinical Practice: Hypothesis and Review. Altern Ther Health Med. 2022 Oct; 28(7):169-177. PMID: 33373322.
      Citations:    Fields:    Translation:Humans
    10. Cede?o E, Cruz A, Cort?s J, Melin K, Roman L, Gonzalez A, Duconge J, Santiago D. Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series. Patient Prefer Adherence. 2022; 16:69-78. PMID: 35046643.
      Citations:    
    11. Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194. PMID: 35077080.
      Citations: 2     Fields:    Translation:Humans
    12. Steiner HE, Giles JB, Patterson HK, Feng J, El Rouby N, Claudio K, Marcatto LR, Tavares LC, Galvez JM, Calderon-Ospina CA, Sun X, Hutz MH, Scott SA, Cavallari LH, Fonseca-Mendoza DJ, Duconge J, Botton MR, Santos PCJL, Karnes JH. Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Front Pharmacol. 2021; 12:749786. PMID: 34776967.
      Citations:    
    13. Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hern?ndez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer. Mol Cancer Ther. 2021 12; 20(12):2420-2432. PMID: 34607932.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    14. Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266. PMID: 34415683.
      Citations: 13     Fields:    Translation:Humans
    15. Vald?s-Fern?ndez BN, Duconge J, Espino AM, Rua?o G. Personalized health and the coronavirus vaccines-Do?individual genetics matter? Bioessays. 2021 09; 43(9):e2100087. PMID: 34309055.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    16. Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 09; 110(3):662-676. PMID: 34109627.
      Citations: 10     Fields:    Translation:Humans
    17. Mariana R Botton, Michelle Whirl-Carrillo, Andria L Del Tredici, Katrin Sangkuhl, Larisa H Cavallari, José A G Agúndez, Jorge Duconge, Ming Ta Michael Lee, Erica L Woodahl, Karla Claudio-Campos, Ann K Daly, Teri E Klein, Victoria M Pratt, Stuart A Scott, Andrea Gaedigk . PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021; 2(109):352-366. View Publication.
    18. Gonzalez-Cordero AF, Duconge-Soler J, Franqui-Rivera H, Feliu-Maldonado R, Roche-Lima A, Almodovar-Rivera I. Insight on the Genetics of Atrial Fibrillation in Puerto Rican Hispanics. Stroke Res Treat. 2021; 2021:8819896. PMID: 33505650.
      Citations:    
    19. Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020 Dec 18; 12(12). PMID: 33352843.
      Citations:    
    20. Reig-L?pez J, Maldonado MDM, Merino-Sanjuan M, Cruz-Collazo AM, Ruiz-Calder?n JF, Mangas-Sanju?n V, Dharmawardhane S, Duconge J. Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. Pharmaceutics. 2020 Oct 15; 12(10). PMID: 33076517.
      Citations:    
    21. El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 01; 14(1):268-276. PMID: 32860733.
      Citations: 5     Fields:    Translation:Humans
    22. Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 Aug 19. PMID: 32809952.
      Citations: 1     Fields:    
    23. Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4). PMID: 34704696.
      Citations:    Fields:    Translation:Humans
    24. Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Rua?o G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 08 06; 10(8):e038936. PMID: 32764090.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    25. Segu? HA, Melin K, Qui?ones DS, Duconge J. A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. J Transl Genet Genom. 2020; 4:263-277. PMID: 33274315.
      Citations:    
    26. Rodr?guez-Escudero I, Cede?o JA, Rodr?guez-Nazario I, Reynaldo-Fern?ndez G, Rodr?guez-Vera L, Morales N, Jim?nez-V?lez B, Rua?o G, Duconge J. Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service. J Am Coll Clin Pharm. 2020 Sep; 3(6):1028-1037. PMID: 32964197.
      Citations:    
    27. Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 06; 107(6):1420-1433. PMID: 31869433.
      Citations: 19     Fields:    Translation:Humans
    28. Roche-Lima A, Roman-Santiago A, Feliu-Maldonado R, Rodriguez-Maldonado J, Nieves-Rodriguez BG, Carrasquillo-Carrion K, Ramos CM, da Luz Sant'Ana I, Massey SE, Duconge J. Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data. Front Pharmacol. 2019; 10:1550. PMID: 32038238.
      Citations:    
    29. Maldonado MDM, Rosado-Gonz?lez G, Bloom J, Duconge J, Ruiz-Calder?n JF, Hern?ndez-O'Farrill E, Vlaar C, Rodr?guez-Orengo JF, Dharmawardhane S. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry. ACS Omega. 2019 Nov 05; 4(19):17981-17989. PMID: 31720502.
      Citations:    
    30. Claudio-Campos K, Moner?-Paredes M, Hern?ndez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902. PMID: 31453773.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    31. Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodr?guez-Maldonado J, Duconge J, Rua?o G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 06; 13(8):649-661. PMID: 31157538.
      Citations: 9     Fields:    Translation:Humans
    32. De la Rosa MVG, Santiago R, Romero JM, Duconge J, Monbaliu JC, L?pez-Mej?as V, Stelzer T. Solubility Determination and Correlation of Warfarin Sodium 2-Propanol Solvate in Pure, Binary, and Ternary Solvent Mixtures. J Chem Eng Data. 2019 Apr 11; 64(4):1399-1413. PMID: 32536719.
      Citations:    
    33. Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83. PMID: 30520344.
      Citations: 1     Fields:    Translation:Humans
    34. Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8. PMID: 30518301.
      Citations: 2     Fields:    Translation:Humans
    35. Duconge J, Rua?o G. Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. Pharmacogenomics. 2018 07 01; 19(11):875-881. PMID: 29898627.
      Citations: 6     Fields:    Translation:Humans
    36. Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J. Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmgenomics Pers Med. 2018; 11:95-106. PMID: 29922082.
      Citations:    
    37. Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6). PMID: 29848980.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    38. Hernandez-Suarez DF, N??ez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55. PMID: 29408797.
      Citations: 5     Fields:    Translation:HumansCells
    39. Reynaldo G, Rodr?guez L, Men?ndez R, Solaz?bal J, Amaro D, de Los A Becquer M, Colom Y, Gil H, Polo JC, Casta?eda G, Jim?nez-V?lez B, Duconge J, Fern?ndez-S?nchez EM. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA? and ior?EPOCIM. J Pharm Pharmacogn Res. 2018 May-Jun; 6(3):179-190. PMID: 30739984.
      Citations:    
    40. Carlos Martes-Martinez; Cristian Méndez-Sepúlveda; Joel Millán-Molina; Matthew French-Kim; Heriberto Marín-Centeno; Giselle C. Rivera-Miranda; José J. Hernández-Muñoz; Jorge Duconge-Soler. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico. P R Health Sci Journal. 2017; 3(36):165-172.
    41. Encarnaci?n-Medina J, Rodr?guez-Cotto RI, Bloom-Oquendo J, Ortiz-Mart?nez MG, Duconge J, Jim?nez-V?lez B. Selective ATP-Binding Cassette Subfamily C Gene Expression and Proinflammatory Mediators Released by BEAS-2B after PM2.5, Budesonide, and Cotreated Exposures. Mediators Inflamm. 2017; 2017:6827194. PMID: 28900313.
      Citations: 1     Fields:    Translation:HumansCells
    42. Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241. PMID: 28675986.
      Citations: 5     Fields:    Translation:HumansCells
    43. Claudio-Campos K, Labastida A, Ramos A, Gaedigk A, Renta-Torres J, Padilla D, Rivera-Miranda G, Scott SA, Rua?o G, Cadilla CL, Duconge-Soler J. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol. 2017; 8:347. PMID: 28638342.
      Citations:    
    44. Jim?nez-Ram?rez FJ, Castro LM, Ortiz C, Concepci?n J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32. PMID: 28231061.
      Citations: 3     Fields:    Translation:Humans
    45. Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17. PMID: 28245774.
      Citations: 8     Fields:    Translation:Humans
    46. Hernandez-Suarez DF, Claudio-Campos K, Mirabal-Arroyo JE, Torres-Hern?ndez BA, L?pez-Candales A, Melin K, Duconge J. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep. 2016 Oct-Dec; 4(4):2324709616682049. PMID: 28210634.
      Citations: 3     Fields:    
    47. C?spedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montan?-Jaime LK, Roblejo H, Fari?as H, Campos ML, Ram?rez R, Serrano V, Villagr?n CI, Pe?as-LLed? EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016 10; 17(15):1707-1724. PMID: 27633613.
      Citations: 1     Fields:    Translation:Humans
    48. Duconge J, Rua?o G. Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016 09; 17(14):1479-82. PMID: 27537834.
      Citations: 4     Fields:    Translation:Humans
    49. Gonz?lez MJ, Berdiel MJ, Miranda-Massari JR, L?pez D, Rodr?guez-L?pez JL, Adrover-L?pez PA, Duconge J. High dose intravenous vitamin c treatment in a patient with lung cancer: A case report. Clin Case Rep Rev. 2016; 2(6):454-455. PMID: 36203911.
      Citations:    
    50. Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Berm?dez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Rua?o G. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One. 2016; 11(1):e0145480. PMID: 26745506.
      Citations: 18     Fields:    Translation:Humans
    51. Miranda-Massari JR, Rodr?guez-G?mez JR, Gonz?lez MJ, Cidre C, Duconge J, Mar?n H, Grace K, McLeod HL. Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. Int J Diabetes Res. 2016; 5(5):92-101. PMID: 28936369.
      Citations:    
    52. Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garc?a R, Hern?ndez G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49. PMID: 26501165.
      Citations: 4     Fields:    Translation:Humans
    53. Duconge J, Rua?o G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015; 16(15):1685-8. PMID: 26431456.
      Citations: 2     Fields:    Translation:Humans
    54. Duconge J, Cadilla CL, Seip RL, Rua?o G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7. PMID: 26454897.
      Citations: 6     Fields:    Translation:Humans
    55. Claudio-Campos K, Duconge J, Cadilla CL, Rua?o G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105. PMID: 25431893.
      Citations: 16     Fields:    Translation:Humans
    56. Miranda-Massari JR, Gonz?lez MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jim?nez Ramirez FJ, Cintr?n K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, V?zquez A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):60-6. PMID: 26434086.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    57. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Mart?nez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):54-9. PMID: 26434085.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    58. Gonz?lez MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jim?nez-Ram?rez FJ, Cintr?n K, Rodr?guez-G?mez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, V?zquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. P R Health Sci J. 2015 Mar; 34(1):3-8. PMID: 25856870.
      Citations: 1     Fields:    Translation:Humans
    59. Miranda-Massari JR, Gonz?lez MJ, Duconge J, Allende-Vigo MZ, Jim?nez-Ram?rez FJ, Hickey S, V?zquez A, Berdiel MJ, Cintr?n K, Rodr?guez-G?mez JR. Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits. P R Health Sci J. 2015 Mar; 34(1):9-13. PMID: 25856871.
      Citations: 1     Fields:    Translation:Humans
    60. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15; 981-982:19-26. PMID: 25594952.
      Citations: 18     Fields:    Translation:Animals
    61. Duconge J. J Pharmacogenomics Pharmacoproteomics. Population Heterogeneity and Genomic Admixture: Relevance for Global Pharmacogenetics. 2014; 5(5):e141. View Publication.
    62. Valent?n II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Rua?o G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104. PMID: 25244877.
      Citations: 5     Fields:    Translation:Humans
    63. Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodr?guez-L?pez JL, Hunninghake R, Cobas-Rosario VJ. High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. J Orthomol Med. 2014; 29(4):154-156. PMID: 25705076.
      Citations:    
    64. Bermudez-Bosch LA, Rivera G, Cruz I, Felici M, Ramos A, Duconge J. . American Journal of Hematology. A Proposal for an Individualized Pharmacogenetic-guided warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. 2014; 89(1):E1. View Publication.
    65. Karla Claudio-Campos K, Orengo-Mercado C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J. . The FASEB Journal. CYP2C9*8 frequency distribution in Puerto Ricans: implications for warfarin dosing. 2014; 28(1):1141.10.
    66. Ramos AS, Alejandro Y, Vazquez J, Valentin I, Rivera G, Cruz I, Cadilla CL, Renta J, Duconge J. . American Journal of Hematology. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. 2014; 89(1):E4. View Publication.
    67. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med. 2013 Dec; 7(6):913-4. PMID: 24266824.
      Citations:    Fields:    Translation:Humans
    68. Ramos AS, Alejandro-Cowan Y, Vazquez J, Valentin I, Rivera G, Renta J, Cruz I, Feliu JF, Cadilla CL, Seip R, Ruaño G, Duconge J. J Thrombosis and Thrombolysis. Pharmacogenetic-driven warfarin dosing algorithm in Puerto Rican patients. In: Warfarin Dosing Management/ Abstract J3. Special Issue: Proceedings of the 12th National Conference on Anticoagulant Therapy. 2013; 3(35):417.
    69. Orengo-Mercado C, Nieves B, L?pez L, Vall?s-Ortiz N, Renta JY, Santiago-Borrero PJ, Cadilla CL, Duconge J. Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27; 4(113). PMID: 24040574.
      Citations:    
    70. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Rua?o G, Duconge J. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec; 13(16):1937-50. PMID: 23215886.
      Citations: 17     Fields:    Translation:Humans
    71. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N. The bio-energetic theory of carcinogenesis. Med Hypotheses. 2012 Oct; 79(4):433-9. PMID: 22809841.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    72. Duconge J, Rua?o G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics. 2012 Jul; 13(10):1097-100. PMID: 22909196.
      Citations: 2     Fields:    Translation:Humans
    73. Valentin II, Rivera G, Nieves M, Vazquez J, Cruz I, Renta J, Feliu JF, Cadilla CL, Duconge J. American Journal of Hematology. A Pharmacogenetic Safety Profile of Puerto Ricans on Warfarin Therapy. A10. THSNA meeting proceedings. 2012; 87(Suppl. 1):S152.
    74. Duconge J, Escalera O, Korchela M, Ruaño G. Clinical Implications of Genetic Admixture in Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1, D. Sanoudou (ed.). In: Clinical Applications of Pharmacogenetics, Chapter 7,. 2012; 151-164. View Publication.
    75. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Rua?o G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18. PMID: 22274142.
      Citations: 10     Fields:    Translation:Humans
    76. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T. Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis. J Orthomol Med. 2012 Jan 01; 27(1):9-12. PMID: 24860238.
      Citations:    
    77. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov; 6(4):260-73. PMID: 22082324.
      Citations: 22     Fields:    Translation:Humans
    78. Seip RL, Duconge J, Ruaño G. Genotype-Guided Statin Therapy. In: Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. A.H.B. Wu and K.T.J. Yeo (eds.). Molecular and Translational Medicine series. Chapter 10; Springer Science & Business Media (Humana Press), LLC, doi: 10.1007/978-1-60761-283-4. 2011; 155-174.
    79. Rodr?guez-V?lez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Vergara C, Rua?o G, Duconge J. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec; 29(4):402-8. PMID: 21261182.
      Citations:    Fields:    Translation:Humans
    80. Gonz?lez MJ, Miranda-Massari JR, Duconge J. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P R Health Sci J. 2010 Dec; 29(4):410-1; author reply 411-2. PMID: 21261184.
      Citations:    Fields:    Translation:Humans
    81. Duconge J, Rua?o G. The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics. 2010 Oct 04; 1(101). PMID: 23227441.
      Citations:    
    82. Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11. PMID: 20488169.
      Citations: 10     Fields:    Translation:Humans
    83. Seip RL, Duconge J, Rua?o G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24. PMID: 20462345.
      Citations: 9     Fields:    Translation:Humans
    84. Gonz?lez MJ, Rosario-P?rez G, Guzm?n AM, Miranda-Massari JR, Duconge J, Lavergne J, Fernandez N, Ortiz N, Quintero A, Mikirova N, Riordan NH, Ricart CM. Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol Med. 2010; 25(1):29-38. PMID: 23565030.
      Citations:    
    85. Lojo L, Duconge J, Santiago-Borrero PJ. Pediatric Blood & Cancer. Integrating Combinatorial CYP2C9 and VKORC1 Genotypes into Clinical Warfarin Management in Puerto Rican Children with Thrombosis: An Illustrative Cases Study. 2010; 54(6):811-P162.
    86. Rua?o G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009 Apr; 10(4):565-77. PMID: 19374515.
      Citations: 19     Fields:    Translation:Humans
    87. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5. PMID: 20073138.
      Citations: 10     Fields:    Translation:Humans
    88. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis. 2009; 19(4):479-80. PMID: 20077595.
      Citations:    Fields:    Translation:Humans
    89. Duconge J, Cadilla CL, Renta JY, Sil?n-Rivera P, Piovanetti P, Garc?a-Berdec?a R, Castro-Rosario LM, Monz?n S, V?lez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8. PMID: 19069365.
      Citations: 9     Fields:    Translation:Humans
    90. Duconge J. Applying organ clearance concepts in a clinical setting. Am J Pharm Educ. 2008 Oct 15; 72(5):121. PMID: 19214275.
      Citations: 2     Fields:    Translation:Humans
    91. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Rua?o G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403. PMID: 18763667.
      Citations: 1     Fields:    Translation:Humans
    92. Rua?o G, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J, Holford TR, Wu AH. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Per Med. 2008 May; 5(3):225-232. PMID: 29783498.
      Citations: 8     Fields:    
    93. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008 Mar; 27(1):7-19. PMID: 18450228.
      Citations: 38     Fields:    Translation:Humans
    94. Ducong? J, Merino N, Alvarez D, Beausoleil I, Fern?ndez-S?nchez E, Rodr?guez L, Burt AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J. 2008 Mar; 27(1):35-41. PMID: 18450231.
      Citations:    Fields:    Translation:HumansAnimals
    95. Duconge J, Miranda-Massari JR, Gonz?lez MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother. 2007 Jun; 41(6):1082-3. PMID: 17519294.
      Citations: 4     Fields:    Translation:Humans
    96. Garc?a-Santana MA, Duconge J, Sarmiento ME, Lanio-Ru?z ME, Becquer MA, Izquierdo L, Acosta-Dom?nguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharm Drug Dispos. 2006 Sep; 27(6):275-83. PMID: 16758502.
      Citations: 3     Fields:    Translation:HumansAnimals
    97. Duconge J. The case of biotech-derived product equivalence: much ado about nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56. PMID: 18666367.
      Citations:    Fields:    Translation:Humans
    98. Ducong? J, Rodr?guez-Vera L, Valenzuela C, Alvarez D, Ram?rez O, de la Luz-Hern?ndez KR, Rabeza-Leg?n EY, Casac? A, Fern?ndez-S?nchez E. Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005 Oct; 61(3):142-8. PMID: 16126380.
      Citations: 3     Fields:    Translation:HumansAnimals
    99. Hern?ndez-Bernal F, Garc?a-Garc?a I, Gonz?lez-Delgado CA, Valenzuela-Silva C, Soto-Hern?ndez R, Ducong? J, Cervantes-Llano M, Blanco-Garc?s E, Rodr?guez V, Garc?a-Vega Y, Bello-Rivero I, Olivera-Ruano L, L?pez-Saura P. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005 May; 26(4):151-9. PMID: 15799006.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    100. Duconge J, Prats PA, Valenzuela C, Aguilera A, Rojas I, Becquer MA, Alvarez D, Estrada L, Alfonso-Ortíz S, Hardy-Rando E, García-Pulpeiro O, Fernández-Sánchez E. Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds. Biopharm Drug Dispos. 2004; 5(25):193-201. View Publication.
    101. Ducong? J, Fern?ndez-S?nchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86. PMID: 15108220.
      Citations: 7     Fields:    Translation:HumansAnimals
    102. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fern?ndez-S?nchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70. PMID: 14757498.
      Citations: 2     Fields:    Translation:HumansAnimals
    103. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducong? J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004; 5(5):271-80. PMID: 15357626.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    104. Duconge J, Fern?ndez-S?nchez E, Mac?as A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5. PMID: 12064367.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    105. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fern?ndez-S?nchez E. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002 Mar; 23(2):67-76. PMID: 11932961.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    106. Fernandez-S?nchez E, Ducong? J, Castillo R, Garcia I, Beausoleil I, Mac?as A. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol. 2002 Jan; 54(1):59-64. PMID: 11829130.
      Citations: 2     Fields:    Translation:Animals
    107. Morales AA, Ducong? J, Alvarez-Ruiz D, Becquer-Viart ML, N??ez-Gandolff G, Fern?ndez E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206. PMID: 10773550.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    108. Morales AA, N??ez-Gandolff G, P?rez NP, V?liz BC, Caballero-Torres I, Ducong? J, Fern?ndez E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl Med Biol. 1999 Aug; 26(6):717-23. PMID: 10587113.
      Citations: 1     Fields:    Translation:HumansAnimals
    109. Morales-Morales A, Ducong? J, Caballero-Torres I, N??ez-Gandolff G, Fern?ndez E, Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9. PMID: 10363798.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    110. Iznaga Escobar N, Morales AM, Ducong? J, Torres IC, Fern?ndez E, G?mez JA. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998 Jan; 25(1):17-23. PMID: 9466357.
      Citations: 2     Fields:    Translation:HumansAnimals
    Duconge's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (296)
    Explore
    _
    Co-Authors (15)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support